New obesity drug RAY1225 enters early human testing

NCT ID NCT05835752

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug, RAY1225, in 68 healthy and obese adults in China. The main goal was to check if the drug is safe and how the body processes it. Researchers also looked at changes in body weight and waist size as early signs of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

RAY1225

What this could lead to

If successful, this could point toward a new treatment for obesity that helps with weight loss.

What could go wrong

This is a very early Phase 1 trial with only 68 people, focused on safety. It may not lead to an effective treatment, and side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nanfang Hospital,South Medical Hospital

    Guangzhou, Guangdong, China